Journal of International Oncology››2014,Vol. 41››Issue (3): 209-211.doi:10.3760/cma.j.issn.1673-422X.2014.03.015
Previous ArticlesNext Articles
LIANG Hai-Peng, YANG Qing-Wei
Online:
2014-03-08Published:
2014-03-17Contact:
Liang Haipeng, E-mail: qylhp@126.com E-mail:qylhp@126.comLIANG Hai-Peng, YANG Qing-Wei. Maspin gene and the invasion and metastasis of gastric cancer[J]. Journal of International Oncology, 2014, 41(3): 209-211.
[1] Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN[J]. Int J Cancer, 2010, 127(12):28932917. [2] Goulet B, Chan G, Chambers AF, et al. An emerging role for the nuclear localization of maspin in the suppression of tumor progression and metastasis[J]. Biochem Cell Biol, 2012,90(1):2238. [3] Berardi R, Morgese F, Onofri A, et al. Role of maspin in cancer[J]. Clin Transl Med,2013,2(1):13261328. [4] Bailey CM, KhalkhaliEllis Z, Seftor EA, et al. Biological functions of maspin[J]. J Cell Physiol, 2006,209(3):617624. [5] Choy B, FindeisHosey JJ, Li F, et al. High frequency of coexpression of maspin with p63 and p53 in squamous cell carcinoma but not in adenocarcinoma of the lung[J]. Int J Clin Exp Pathol, 2013, 6(11):25422547. [6] Zheng AH, Yi YF, Zhou WW. Construction of a eukaryotic vector expressing MASPIN gene and its effect on cell apoptosis in gastric cancer cell line SGC7901[J].Ai Zheng, 2008, 27(11):11611165. [7] 倪江涛, 石海鹏, 易永芬. RNA干扰maspin基因对胃癌细胞株MKN28凋亡的影响[J]. 肿瘤, 2010,30(7):571573. [8] Cesca M, Bizzaro F, Zucchetti M, et al. Tumor Delivery of Chemotherapy Combined with Inhibitors of Angiogenesis and Vascular Targeting Agents[J]. Front Oncol, 2013, 3:259. [9] Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis[J]. Oncology, 2011, 81(1):2429. [10] 白玉贤, 易继林, 王树叶. 胃癌组织中Maspin蛋白与血管内皮生长因子C的表达及其相关性肿瘤[J]. 肿瘤防治研究, 2007, 34(8):6063. [11] Okayama H, Kumamoto K, Saitou K, et al. CD44v6, MMP7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer[J]. Oncol Rep, 2009, 22(4):745755. [12] Yang Y, Shi H, Li X, et al. Effects of shRNA targeting maspin on invasion of gastric carcinoma SGC7901 cell line[J]. Oncol Rep, 2011, 25(1):259265. [13] Ito R, Nakayama H, Yoshida K, et al. Loss of maspin expression is associated with development and progression of gastric carcinoma with p53 abnormality[J]. Oncol Rep, 2004, 12(5):985890. [14] Oshiro MM, Watts GS, Wozniak RJ, et al. Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression[J]. Oncogene, 2003, 22(23):36243634. [15] Bodenstine TM, Seftor RE, KhalkhaliEllis Z, et al. Maspin: molecular mechanisms and therapeutic implications[J]. Cancer Metastasis Rev,2012,31(34):529551. [16] Lockett J, Yin S, Li X, Meng Y, et al. Tumor suppressive maspin and epithelial homeostasis[J]. J Cell Biochem, 2006, 97(4):651660. |
[1] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[2] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[3] | Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165. |
[4] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[5] | Shao Huifang, Wang Xuehong, Lu Yongfu.Mechanism of action and clinical significance of CST1 in the progression of gastric cancer[J]. Journal of International Oncology, 2023, 50(8): 489-492. |
[6] | Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu.Level of serum FABP1 and its relationship withHelicobacter pyloriinfection in patients with gastric cancer[J]. Journal of International Oncology, 2023, 50(6): 336-341. |
[7] | Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207. |
[8] | Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen.Correlation between blood lipid level and gastric cancer[J]. Journal of International Oncology, 2023, 50(3): 183-185. |
[9] | Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen.Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 112-116. |
[10] | Yang Jun, Li Rong, Zeng Jianchang.Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 82-86. |
[11] | Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757. |
[12] | Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan.Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer[J]. Journal of International Oncology, 2023, 50(11): 677-682. |
[13] | Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei.Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(10): 631-635. |
[14] | Zhao Jianhao, Duan Yanchao.Research progress in the pathogenesis of extramedullary disease in multiple myeloma[J]. Journal of International Oncology, 2023, 50(1): 55-59. |
[15] | Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali.Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer[J]. Journal of International Oncology, 2022, 49(5): 276-281. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||